{"version":"1.0","type":"link","title":"TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.","author_name":"Jacob S 외","author_url":"https://prs-insight.online/author/Jacob%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/78351","thumbnail_width":1200,"thumbnail_height":630}